What’s the problem? [Bioanalytics]

posted by auditor – India, 2012-02-13 06:35 (5249 d 15:45 ago) – Posting: # 8112
Views: 8,592

❝ ❝ In India we always tried to give appropriate dilution to the taken weight to get the concentration of nominal within the validated range.

❝ How to you do that (“appropriate dilution”)?


in that we are targeting required concentration. After acheiving that concentration we prepare remaining level of the curve by serial dilution. this way we always prepare all the level within the establish calibration curve.

❝ ❝ Might be regulatory having different approach while auditing data generated in India and over sea's.


❝ Can you give an example of regulatory problems by the CDSCO/DCGI?


I am no talking about CDSCO/ DCGI. I am talking about US FDA. In one of the meeting we have discuss this point and they suggest to have all the level within the establish calibration curve. (Sorry i can not give name of the agency inspector)

❝ Deviation –1%: no problem.


this will allow us to prepare calibration curve level within the range.

❝ In validation you weighed in 19.9 mg and in the study 20.1 mg.

❝ Deviation +1%: problem. Why?


We do not worry about +1% deviation. as we are adjusting concentration by dilution.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
388 visitors (0 registered, 388 guests [including 106 identified bots]).
Forum time: 23:21 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5